ArticleFrontiers in digital health2026
Feasibility of weekly patient-reported symptom monitoring using patients' own smartphones in outpatient cancer chemotherapy: the SMART-PRO study.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electronic patient-reported outcome (ePRO) systems using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) can improve symptom monitoring, but the feasibility of implementing such systems with a bring-your-own-device (BYOD) approach in routine oncology practice, particularly among older adults, is not well established. We conducted a single-arm prospective observational study in Japan to evaluate weekly BYOD-based ePRO monitoring of adverse events in outpatients receiving chemotherapy. Twenty-eight patients used smartphones to complete weekly PRO-CTCAE/CTCAE-based questionnaires for 12 weeks. Alerts were automatically generated when severity or frequency thresholds were met. Feasibility outcomes were weekly ePRO response rates and the distribution of alert-generating symptoms; HRQoL (EORTC QLQ-C30) was assessed at baseline, week 6, and week 12. The mean age was 66.7 years and most patients had stage IV disease. The weekly ePRO response rate ranged from 75% to 93% in the overall cohort and remained at or above 75% in patients aged ≥70 years. Pain-related items most frequently triggered alerts, followed by numbness and tingling, rash, fatigue, and skin-related disorders. The EORTC QLQ-C30 global health status score increased numerically from 54.8 at baseline to 63.5 at week 6 and 63.4 at week 12, with no marked deterioration observed over 12 weeks. These findings indicate that weekly PRO-CTCAE/CTCAE-based ePRO monitoring using a BYOD approach is feasible in routine outpatient oncology care, including among older adults who use smartphones. This study provides preliminary evidence for BYOD-based ePRO implementation in this underexplored population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.